A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
 
Sponsors and Collaborators
 
Contact
Ramaprasad Srinivasan, M.D.
(301) 496-6353
 
Investigators
Ramaprasad Srinivasan, M.D.
National Cancer Institute (NCI)
 
ClinicalTrials.gov Identifier